Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Real-time quantitative PCR analysis of extracellular vesicle miRNA from human U2OS cells culture medium [FZD4]

ABSTRACT: Real-time quantitative PCR analysis of extracellular vesicle miRNA from human U2OS cells culture medium [FZD4]

PROVIDER: PRJNA1124958 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Real-time quantitative PCR analysis of extracellular vesicle miRNA from human U2OS cells culture medium [FZD4]

Project description:Human U2OS cells were stimulated with selective agonist Wnt3a of Frizzled class receptor 4(FZD4) for 24 hours. Extracellular vesicles were isolated from U2OS cell culture media. Total RNAs were purified from extracellular vesicle samples. We used TaqMan Low Density Arrays to quantitate miRNA expression in extracellular vesicles secreted by U2OS cells after GPCR activation.

2025-07-30 | GSE270079 | GEO

Real-time quantitative PCR analysis of extracellular vesicle miRNA from human U2OS cells culture medium [HRH1]

Project description:Human U2OS cells were stimulated with selective agonist PEA of Histamine receptor H1 (HRH1) for 24 hours. Extracellular vesicles were isolated from U2OS cell culture media. Total RNAs were purified from extracellular vesicle samples. We used TaqMan Low Density Arrays to quantitate miRNA expression in extracellular vesicles secreted by U2OS cells after GPCR activation.

2025-07-30 | GSE270080 | GEO

Real-time quantitative PCR analysis of extracellular vesicle miRNA from human U2OS cells culture medium [AODRA1]

Project description:Human U2OS cells were stimulated with selective agonist CCPA of adenosine receptor A1(ADORA1) for 24 hours. Extracellular vesicles were isolated from U2OS cell culture media. Total RNAs were purified from extracellular vesicle samples. We used TaqMan Low Density Arrays to quantitate miRNA expression in extracellular vesicles secreted by U2OS cells after GPCR activation.

2025-07-30 | GSE270078 | GEO

Real-time quantitative PCR analysis of extracellular vesicle miRNA from human U2OS cells culture medium [ACKR3]

Project description:Human U2OS cells were stimulated with selective agonist SDF-1 of atypical chemokine receptor 3 (ACKR3) for 24 hours. Extracellular vesicles were isolated from U2OS cell culture media. Total RNAs were purified from extracellular vesicle samples. We used TaqMan Low Density Arrays to quantitate miRNA expression in extracellular vesicles secreted by U2OS cells after GPCR activation.

2025-07-30 | GSE270077 | GEO

Real-time quantitative PCR analysis of extracellular vesicle miRNA from human U2OS cells culture medium [AODRA1]

Project description:Real-time quantitative PCR analysis of extracellular vesicle miRNA from human U2OS cells culture medium [AODRA1]

| PRJNA1124959 | ENA

Real-time quantitative PCR analysis of extracellular vesicle miRNA from human U2OS cells culture medium [HRH1]

Project description:Real-time quantitative PCR analysis of extracellular vesicle miRNA from human U2OS cells culture medium [HRH1]

| PRJNA1124957 | ENA

Real-time quantitative PCR analysis of extracellular vesicle miRNA from human U2OS cells culture medium [ACKR3]

Project description:Real-time quantitative PCR analysis of extracellular vesicle miRNA from human U2OS cells culture medium [ACKR3]

| PRJNA1124955 | ENA

FOXF1 Promotes Tumor Vessel Normalization and Prevents Lung Cancer Progression through FZD4

Project description:Cancer cells re-program normal lung endothelial cells (EC) into tumor-associated endothelial cells (TEC) that form leaky vessels supporting carcinogenesis. Transcriptional regulators that control reprogramming of EC into TEC are poorly understood. We identified Forkhead box F1 (FOXF1) as a critical regulator of EC-to-TEC transition. FOXF1 was highly expressed in normal lung vasculature but was decreased in TEC within non-small cell lung cancers (NSCLC). Low FOXF1 correlated with poor overall survival of NSCLC patients. In mice, endothelial-specific deletion of FOXF1 decreased pericyte coverage, increased vessel permeability and hypoxia, and promoted lung tumor growth and metastasis. Endothelial-specific over-expression of FOXF1 normalized tumor vessels and inhibited progression of lung cancer. FOXF1-deficiency decreased Wnt/β-catenin signaling in TECs through direct transcriptional activation of Fzd4. Restoring FZD4 expression in FOXF1-deficient TECs through endothelial-specific nanoparticle delivery of Fzd4 cDNA rescued Wnt/β-catenin signaling in TECs, normalized tumor vessels and inhibited progression of lung cancer. Altogether, FOXF1 increases tumor vessel stability, and inhibits lung cancer progression by stimulating FZD4/Wnt/β-catenin signaling in TECs. Nanoparticle delivery of FZD4 cDNA has a promise for future therapies in NSCLC.

2024-03-09 | GSE255969 | GEO

Therapeutic modulation of the blood-brain barrier and ischemic stroke by a bioengineered FZD4-selective WNT surrogate

Project description:Derangements of the blood-brain barrier (BBB) or blood-retinal barrier (BRB) occur in disorders ranging from stroke, cancer, diabetic retinopathy, and Alzheimer's disease. The Norrin/FZD4/TSPAN12 pathway activates WNT/-catenin signaling, which is essential for BBB and BRB function. However, systemic pharmacologic FZD4 stimulation is hindered by obligate palmitoylation and insolubility of native WNTs and suboptimal properties of the FZD4-selective ligand Norrin. Here, we developed L6-F4-2, a non-lipidated, FZD4-specific surrogate with significantly improved sub-picomolar affinity versus native Norrin. In Norrin knockout (NdpKO) mice, L6-F4-2 not only potently reversed neonatal retinal angiogenesis deficits, but also restored BRB and BBB function. In adult C57Bl/6J mice, post-stroke systemic delivery of L6-F4-2 strongly reduced BBB permeability, infarction, and edema, while improving neurologic score and capillary pericyte coverage. Our findings reveal systemic efficacy of a bioengineered FZD4-selective WNT surrogate during ischemic BBB dysfunction, with general applicability to adult CNS disorders characterized by an aberrant blood-brain barrier.

2023-01-31 | GSE223498 | GEO

U2OS-ERa, U2OS-ERb, and U2OS-ERab cells treated with 4HT or E2

Project description:U2OS-ERa, U2OS-ERb, and U2OS-ERab cells treated with 4HT or E2 Keywords: other

2005-04-06 | GSE2292 | GEO